197 related articles for article (PubMed ID: 35004285)
1. Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells.
Piotrowska A; Beserra FP; Wierzbicka JM; Nowak JI; Żmijewski MA
Front Oncol; 2021; 11():763895. PubMed ID: 35004285
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
Wasiewicz T; Piotrowska A; Wierzbicka J; Slominski AT; Zmijewski MA
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200275
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D.
Piotrowska A; Nowak JI; Wierzbicka JM; Domżalski P; Górska-Arcisz M; Sądej R; Popiel D; Wieczorek M; Żmijewski MA
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473753
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D Modulates the Response of Patient-Derived Metastatic Melanoma Cells to Anticancer Drugs.
Piotrowska A; Zaucha R; Król O; Żmijewski MA
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175742
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.
Piotrowska A; Wierzbicka J; Rybarczyk A; Tuckey RC; Slominski AT; Żmijewski MA
Int J Oncol; 2019 Apr; 54(4):1481-1495. PubMed ID: 30968156
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.
Reichrath J; Rech M; Moeini M; Meese E; Tilgen W; Seifert M
Cancer Biol Ther; 2007 Jan; 6(1):48-55. PubMed ID: 17172823
[TBL] [Abstract][Full Text] [Related]
7. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative Activity of Double Point Modified Analogs of 1,25-Dihydroxyvitamin D₂ Against Human Malignant Melanoma Cell Lines.
Piotrowska A; Wierzbicka J; Nadkarni S; Brown G; Kutner A; Żmijewski MA
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26760999
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of side-chain truncated vitamin D analogs (PRI-1203 and PRI-1204) against human malignant melanoma cell lines.
Piotrowska A; Wierzbicka J; Kwiatkowska K; Chodyński M; Kutner A; Żmijewski MA
Eur J Pharmacol; 2020 Aug; 881():173170. PubMed ID: 32445704
[TBL] [Abstract][Full Text] [Related]
10. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells.
Essa S; Denzer N; Mahlknecht U; Klein R; Collnot EM; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):110-3. PubMed ID: 20153427
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
12. Activation of vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines.
Sertznig P; Seifert M; Tilgen W; Reichrath J
Dermatoendocrinol; 2009 Jul; 1(4):232-8. PubMed ID: 20592797
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
14. A Reconstructed Human Melanoma-in-Skin Model to Study Immune Modulatory and Angiogenic Mechanisms Facilitating Initial Melanoma Growth and Invasion.
Michielon E; López González M; Stolk DA; Stolwijk JGC; Roffel S; Waaijman T; Lougheed SM; de Gruijl TD; Gibbs S
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345186
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.
Morelli MP; Brown AM; Pitts TM; Tentler JJ; Ciardiello F; Ryan A; Jürgensmeier JM; Eckhardt SG
Mol Cancer Ther; 2009 Sep; 8(9):2546-58. PubMed ID: 19755510
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation.
Albino AP; Juan G; Traganos F; Reinhart L; Connolly J; Rose DP; Darzynkiewicz Z
Cancer Res; 2000 Aug; 60(15):4139-45. PubMed ID: 10945621
[TBL] [Abstract][Full Text] [Related]
17. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
Essa S; Reichrath S; Mahlknecht U; Montenarh M; Vogt T; Reichrath J
Anticancer Res; 2012 Jan; 32(1):383-9. PubMed ID: 22213330
[TBL] [Abstract][Full Text] [Related]
18. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
[TBL] [Abstract][Full Text] [Related]
19. Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro.
Shannan B; Seifert M; Leskov K; Boothman D; Pföhler C; Tilgen W; Reichrath J
Anticancer Res; 2006; 26(4A):2707-16. PubMed ID: 16886681
[TBL] [Abstract][Full Text] [Related]
20. Ailanthone Induces Cell Cycle Arrest and Apoptosis in Melanoma B16 and A375 Cells.
Liu W; Liu X; Pan Z; Wang D; Li M; Chen X; Zhou L; Xu M; Li D; Zheng Q
Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31336757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
